Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 22

Results For "CE"

11025 News Found

Telangana life sciences ecosystem reaches $145 billion valuation
Biotech | May 15, 2026

Telangana life sciences ecosystem reaches $145 billion valuation

The state has received Rs. 84,000 crore investments in the sector over two years, positioning Hyderabad among the world’s leading life sciences clusters


Lupin receives USFDA nod for Famotidine injection
Drug Approval | May 15, 2026

Lupin receives USFDA nod for Famotidine injection

Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market


Alembic Pharma receives USFDA tentative approval for Darolutamide tablets
Drug Approval | May 15, 2026

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States


OneSource records Rs. 4,282 million revenue in Q4 FY26
News | May 15, 2026

OneSource records Rs. 4,282 million revenue in Q4 FY26

Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold


Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care
News | May 15, 2026

Lilly and UNICEF launch $50M push to reach 30 million children with life-saving health care

The target reach is of more than 30 million young people and caregivers across 21 countries


Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer
Clinical Trials | May 15, 2026

Imfinzi-based regimens deliver major survival gains in muscle-invasive bladder cancer

The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents


Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook
News | May 14, 2026

Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros


Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
News | May 14, 2026

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion